Clene Inc. (CLNN) Stock

About Clene Inc.

Clene Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to the discovery, advancement, and market introduction of pioneering therapeutic agents utilizing clean-surfaced nanotechnology (CSN). CNM-Au8 stands as its flagship compound, currently under evaluation across a diverse range of clinical studies. This includes a pivotal Phase 2/3 study intended for regulatory submission in individuals battling amyotrophic lateral sclerosis (ALS). The company has successfully concluded a Phase 2 proof-of-concept trial for those with early manifestations of ALS. Furthermore, two open-label, investigator-blinded Phase 2 trials assessing brain energy metabolism have been finished. An ongoing Phase 2 trial is investigating CNM-Au8's potential to mitigate visual pathway deficits stemming from chronic optic neuropathy, aiming for remyelination in stable relapsing Multiple Sclerosis patients. A Phase 2 clinical investigation targeting Parkinson's Disease patients is also slated for commencement. Beyond its leading candidate, Clene's pipeline extends to include CNM-AgZn17. This gel formulation, comprising silver and zinc ions, is in development to combat infectious diseases and hasten wound recovery. Additionally, CNM-ZnAg acts as a broad-spectrum antiviral and antibacterial compound, designed to address various infectious conditions like COVID-19, while also offering immune support for symptom alleviation. For oncology, CNM-PtAu7 is a gold-platinum CSN therapeutic agent currently in development. The company also distributes dietary supplements, featuring rMetx, a liquid supplement containing zinc-silver ions, and KHC46, an aqueous gold supplement with trace amounts of gold nanoparticles. Clene Inc. maintains its headquarters in Salt Lake City, Utah.

Clene Inc. is led by CEO Robert Etherington, employs 75 people, headquartered in US, publicly traded since 2018.

Clene Inc. (CLNN) stock trades at $3.88 with a market capitalization of $55.15M. The stock is valued at a negative price-to-earnings (P/E) ratio of -0.93, reflecting a net loss over the last twelve months, a negative price-to-book of -1.65, reflecting negative shareholders' equity, price-to-sales of 214.70. Over the past 52 weeks the stock has ranged between $3.02 and $13.50, and currently trades 71.3% below its 52-week high.

On profitability, Clene Inc. generates a return on equity (ROE) of 214.97% (not meaningful, as shareholders' equity is negative), return on capital employed of -111.61%, a net profit margin of -250.10%.

Official website: clene.com

Clene Inc. by the numbers, 2017–2025

Between 2017 and 2025 Clene Inc. reported revenue of $0 rising to $0. Compounded, revenue has grown —% a year over five years, —% over three, —% over the last twelve months. Net profit was $-26.0M in 2025.

The most recent net margin is -250.10%. On a trailing twelve-month basis to Jun '26, revenue is $0 and net profit $-39.0M.

Borrowings stand at $22.0M, cash from operations was $-19.0M in the latest year, positive in 0 of the last 9.

Return on equity has averaged -176.8% over five years, and was 144.4% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Clene Inc. (CLNN) — frequently asked questions